Welcome to our dedicated page for Teva Pharmaceutical Industries SEC filings (Ticker: TEVJF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Teva Pharmaceutical Industries's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Teva Pharmaceutical Industries's regulatory disclosures and financial reporting.
Teva Pharmaceutical Industries President and CEO Richard Francis reported vesting and related transactions in company equity on March 5, 2026. He exercised 42,452 Restricted Share Units (RSUs), which converted into the same number of ordinary shares at a stated price of $0.00 per share.
Following the RSU conversion, he held 1,190,664 ordinary shares before selling 20,025 ordinary shares in open-market transactions at a weighted average price of $31.6684 per share to cover tax withholding obligations. After these sales, he directly owns 1,170,639 ordinary shares and 127,359 RSUs, each RSU representing a contingent right to one ordinary share or its cash value. The sale was made under a pre-arranged Rule 10b5-1 trading plan. Ordinary shares may be represented by American Depositary Shares on a one-for-one basis.
Teva Pharmaceutical Industries President and CEO Richard Francis reported vesting and related transactions in company equity on March 5, 2026. He exercised 42,452 Restricted Share Units (RSUs), which converted into the same number of ordinary shares at a stated price of $0.00 per share.
Following the RSU conversion, he held 1,190,664 ordinary shares before selling 20,025 ordinary shares in open-market transactions at a weighted average price of $31.6684 per share to cover tax withholding obligations. After these sales, he directly owns 1,170,639 ordinary shares and 127,359 RSUs, each RSU representing a contingent right to one ordinary share or its cash value. The sale was made under a pre-arranged Rule 10b5-1 trading plan. Ordinary shares may be represented by American Depositary Shares on a one-for-one basis.
Teva Pharmaceutical Industries Ltd EVP, U.S. Commercial Christine Fox reported RSU vesting and related share transactions. On March 5, 2026, 17,819 restricted share units were exercised into the same number of ordinary shares at a stated price of $0.00 per share.
On the same date, she sold 7,924 ordinary shares at a weighted average price of $31.6684 per share to cover tax withholding obligations, under a Rule 10b5-1 trading plan adopted on August 11, 2025. Following these transactions, she directly held 84,905 ordinary shares.
Teva Pharmaceutical Industries Ltd EVP, U.S. Commercial Christine Fox reported RSU vesting and related share transactions. On March 5, 2026, 17,819 restricted share units were exercised into the same number of ordinary shares at a stated price of $0.00 per share.
On the same date, she sold 7,924 ordinary shares at a weighted average price of $31.6684 per share to cover tax withholding obligations, under a Rule 10b5-1 trading plan adopted on August 11, 2025. Following these transactions, she directly held 84,905 ordinary shares.
Teva Pharmaceutical Industries executive Eric A. Hughes reported equity awards activity and a related share sale. On March 5, 2026, 19,654 restricted share units vested and were converted into 19,654 ordinary shares at no cost, increasing his direct holdings to 117,244 ordinary shares.
On the same date, he sold 9,533 ordinary shares at a weighted average price of $31.6684 per share, reducing his direct holdings to 107,711 ordinary shares. According to the disclosure, these shares were sold under a pre-established Rule 10b5-1 trading plan and were required to cover tax withholding obligations from the RSU vesting.
Footnotes add that each restricted share unit represents a right to receive one ordinary share or its cash value, and that the RSU grant from March 5, 2025 vests in four equal annual installments through March 5, 2029.
Teva Pharmaceutical Industries executive Eric A. Hughes reported equity awards activity and a related share sale. On March 5, 2026, 19,654 restricted share units vested and were converted into 19,654 ordinary shares at no cost, increasing his direct holdings to 117,244 ordinary shares.
On the same date, he sold 9,533 ordinary shares at a weighted average price of $31.6684 per share, reducing his direct holdings to 107,711 ordinary shares. According to the disclosure, these shares were sold under a pre-established Rule 10b5-1 trading plan and were required to cover tax withholding obligations from the RSU vesting.
Footnotes add that each restricted share unit represents a right to receive one ordinary share or its cash value, and that the RSU grant from March 5, 2025 vests in four equal annual installments through March 5, 2029.
Teva Pharmaceutical Industries EVP, Europe Commercial Daniell Richard reported equity award activity and a share sale. On March 5, 2026, he exercised 17,295 restricted share units for 17,295 ordinary shares at no cost, as part of a previously granted award. The same day, he sold 17,295 ordinary shares in open-market transactions at a weighted average price of $31.6684, under a Rule 10b5-1 trading plan adopted on November 10, 2025, and in connection with the vesting of the units, including shares sold to cover tax withholding obligations. Following these transactions, he directly holds 85,755 ordinary shares and 51,887 restricted share units.
Teva Pharmaceutical Industries EVP, Europe Commercial Daniell Richard reported equity award activity and a share sale. On March 5, 2026, he exercised 17,295 restricted share units for 17,295 ordinary shares at no cost, as part of a previously granted award. The same day, he sold 17,295 ordinary shares in open-market transactions at a weighted average price of $31.6684, under a Rule 10b5-1 trading plan adopted on November 10, 2025, and in connection with the vesting of the units, including shares sold to cover tax withholding obligations. Following these transactions, he directly holds 85,755 ordinary shares and 51,887 restricted share units.
TEVA PHARMACEUTICAL INDUSTRIES LTD officer Jover Placid reported restricted share units vesting and related share sales. On March 5, 2026, 14,150 restricted share units were exercised into 14,150 ordinary shares at $0.0000 per share.
The same day, he sold 14,150 ordinary shares at a weighted average price of $31.6684 per share in open-market transactions under a Rule 10b5-1 trading plan adopted on November 10, 2025. The sale included shares to cover tax withholding on vesting. Following these transactions, he directly holds 6,774 ordinary shares and 42,453 restricted share units.
TEVA PHARMACEUTICAL INDUSTRIES LTD officer Jover Placid reported restricted share units vesting and related share sales. On March 5, 2026, 14,150 restricted share units were exercised into 14,150 ordinary shares at $0.0000 per share.
The same day, he sold 14,150 ordinary shares at a weighted average price of $31.6684 per share in open-market transactions under a Rule 10b5-1 trading plan adopted on November 10, 2025. The sale included shares to cover tax withholding on vesting. Following these transactions, he directly holds 6,774 ordinary shares and 42,453 restricted share units.
Teva Pharmaceutical Industries interim chief legal officer Brian Savage reported equity compensation activity involving restricted share units and ordinary shares. On March 5, 2026, 3,580 restricted share units were converted into 3,580 ordinary shares at a stated price of $0.00 per share, reflecting a vesting event rather than a market purchase. On the same date, he sold 1,127 ordinary shares at a weighted average price of $31.6684 per share, with the shares sold in multiple trades between $31.26 and $32.34. According to the disclosure, these shares were required to be sold to cover tax withholding obligations arising from the vesting of the restricted share units.
Teva Pharmaceutical Industries interim chief legal officer Brian Savage reported equity compensation activity involving restricted share units and ordinary shares. On March 5, 2026, 3,580 restricted share units were converted into 3,580 ordinary shares at a stated price of $0.00 per share, reflecting a vesting event rather than a market purchase. On the same date, he sold 1,127 ordinary shares at a weighted average price of $31.6684 per share, with the shares sold in multiple trades between $31.26 and $32.34. According to the disclosure, these shares were required to be sold to cover tax withholding obligations arising from the vesting of the restricted share units.
Teva Pharmaceutical Industries executive Matthew Shields exercised 17,295 restricted share units into ordinary shares and, on the same day, sold 17,295 ordinary shares in an open-market transaction at a weighted average price of $31.6684. The sale was executed under a Rule 10b5-1 trading plan adopted on November 10, 2025 and included shares sold to cover tax withholding obligations tied to vesting. Following these transactions, Shields directly holds 9,989 ordinary shares and 51,887 restricted share units.
Teva Pharmaceutical Industries executive Matthew Shields exercised 17,295 restricted share units into ordinary shares and, on the same day, sold 17,295 ordinary shares in an open-market transaction at a weighted average price of $31.6684. The sale was executed under a Rule 10b5-1 trading plan adopted on November 10, 2025 and included shares sold to cover tax withholding obligations tied to vesting. Following these transactions, Shields directly holds 9,989 ordinary shares and 51,887 restricted share units.
Teva Pharmaceutical Industries President and CEO Richard Francis reported multiple equity transactions on ordinary shares and restricted share units. He exercised 50,223 restricted share units, receiving the same number of ordinary shares at a price of $0.00 per share, as part of a prior equity grant.
On the same date, he received a new award of 136,736 restricted share units, each representing a right to one ordinary share or its cash value at settlement. He then sold 23,393 ordinary shares at a weighted average price of $32.4645 per share, with the shares sold at prices between $32.095 and $33.30 to cover tax withholding obligations under a pre-established Rule 10b5-1 trading plan.
Following these transactions, Francis held 1,148,212 ordinary shares directly.
Teva Pharmaceutical Industries President and CEO Richard Francis reported multiple equity transactions on ordinary shares and restricted share units. He exercised 50,223 restricted share units, receiving the same number of ordinary shares at a price of $0.00 per share, as part of a prior equity grant.
On the same date, he received a new award of 136,736 restricted share units, each representing a right to one ordinary share or its cash value at settlement. He then sold 23,393 ordinary shares at a weighted average price of $32.4645 per share, with the shares sold at prices between $32.095 and $33.30 to cover tax withholding obligations under a pre-established Rule 10b5-1 trading plan.
Following these transactions, Francis held 1,148,212 ordinary shares directly.
Teva Pharmaceutical Industries EVP, Europe Commercial Daniell Richard reported a combination of equity awards, vesting and share sales. On March 4, 2026, he exercised restricted share units into 33,512 and 20,461 ordinary shares and received a new grant of 33,424 restricted share units.
He then sold 91,345 ordinary shares in open-market transactions at weighted average prices of $32.4645 and $32.9474, executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 10, 2025. Following these trades, he directly owned 85,755 ordinary shares. The filing notes the sales related to vesting of restricted share units, including shares sold to cover tax withholding obligations.
Teva Pharmaceutical Industries EVP, Europe Commercial Daniell Richard reported a combination of equity awards, vesting and share sales. On March 4, 2026, he exercised restricted share units into 33,512 and 20,461 ordinary shares and received a new grant of 33,424 restricted share units.
He then sold 91,345 ordinary shares in open-market transactions at weighted average prices of $32.4645 and $32.9474, executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 10, 2025. Following these trades, he directly owned 85,755 ordinary shares. The filing notes the sales related to vesting of restricted share units, including shares sold to cover tax withholding obligations.
Jover Placid reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD reported that officer Jover Placid received a grant of 37,982 restricted share units on March 4, 2026. Each restricted share unit represents a contingent right to receive one ordinary share, or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share.
The award vests in four annual installments, with 9,495 units vesting on each of March 4, 2027, March 4, 2028, and March 4, 2029, and 9,497 units vesting on March 4, 2030. The ordinary shares may be represented by American Depositary Shares, each currently corresponding to one ordinary share.
Jover Placid reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD reported that officer Jover Placid received a grant of 37,982 restricted share units on March 4, 2026. Each restricted share unit represents a contingent right to receive one ordinary share, or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share.
The award vests in four annual installments, with 9,495 units vesting on each of March 4, 2027, March 4, 2028, and March 4, 2029, and 9,497 units vesting on March 4, 2030. The ordinary shares may be represented by American Depositary Shares, each currently corresponding to one ordinary share.